It is demonstrated that sparganosis induces pronounced IgE-dependent osteoclastogenesis and severe bone destruction and Omalizumab is a candidate for a potential therapeutic strategy to alleviate osteolysis in SS patients.
Abstract
Progressive multi-vertebral osteolysis, frequently misdiagnosed as malignancy or tuberculosis, can also be driven by a previously unrecognized infectious trigger. Here we demonstrate that sparganosis induces pronounced IgE-dependent osteoclastogenesis and severe bone destruction. Single-cell RNA analysis of peripheral blood mononuclear cells identified the immune cell landscape of spinal sparganosis (SS) and the immunoglobulin-related pathways upregulated in naïve B cells derived from SS. Notably, the sparganosis triggers osteoclast activation and subsequent bone destruction. IgE was found at a dramatically high level in SS and played a critical driver of osteoclast activity and osteolysis. Notably, >90% of this IgE proved non-plerocercoid-specific, indicating that infection triggers an IgE hyper-response which sustains osteoclast activation. Mechanistically, IgE binding to the low-affinity Fc epsilon receptor II (FcεRII) using its Fc part, followed by upregulating the expression and nuclear translocation of NFATc1 via activating the AKT/ERK signaling pathway, promotes osteoclast precursor cells differentiation and bone resorption. Importantly, Omalizumab, the only marketed drug of monoclonal anti-IgE antibodies, could compromise the osteoclastogenesis induced by IgE and SS plasma. These findings provide novel insights into the immunopathological mechanisms of IgE in promoting osteolytic destruction in SS, and Omalizumab is a candidate for a potential therapeutic strategy to alleviate osteolysis in SS patients.
Age-related bone loss is driven in part by inflammatory remodeling of the bone marrow niche, which promotes macrophage activation and osteoclastogenesis. Atractylenolide III (AT-III) is a chemically defined sesquiterpene lactone with anti-inflammatory activity, but its skeletal effects in natural aging remain unclear....
Cheng Xiang, Wen-Yuan Xiang, Jannatul Ferdus Shila et al.· Bone Reports· 0 citations
Findings indicate that 3-MC mitigates osteoclast differentiation and oxidative stress, accompanied by downregulation of the Notch2 signaling axis, highlighting its potential as a promising therapeutic candidate for bone-related disorders.
D. Lee, Yeo Rang Cho, Ki Hyun Kim et al.· Biochemical Pharmacology· 0 citations
Osteopontin (OPN) is a secreted phosphoprotein that is abundant in the bone matrix and plays an important role in bone homeostasis. Cortical bone in OPNnull mice has a heterogenous mineral density and reduced fracture toughness indicative of a defect in bone homeostasis. Osteoclasts binding to bone appears to be mediat...
Christopher Grieg, Hsuan-Ni Lin, J. P. O'Connor· Cellular Signalling· 0 citations
Osteoimmunology explores the interplay between the skeletal system and the immune system. It focuses on the identification of shared signaling pathways and the mechanisms of mutual regulation. Bone homeostasis depends on the balance between the activity of bone-forming osteoblasts and bone-resorbing osteoclasts. Intere...
Marina Kleim, Aline Bozec, Manuel Weber et al.· Bone Research· 0 citations
Lack of Gba1 activity induced changes in the osteoclast model which enhanced its bone resorption potential, demonstrating a major intrinsic osteoclastic defect in Gaucher disease of bone.
J. Patiño-Salazar, J. D. Gutiérrez-Ávila, S. Heredero-Jiménez et al.· Calcified Tissue Internation...· 0 citations
Glucocorticoid-induced osteoporosis (GIOP) is characterized by progressive cortical bone fragility accompanied by osteocyte lacunar enlargement and peri-lacunar osteolysis. However, whether these microstructural alterations arise from a specific cell death program remains unclear. Here, we demonstrate that glucocorti...
Xing Rong, Qing-Hua Ren, Y. Kou et al.· Cell Death Discovery· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.